Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
Status:
Completed
Trial end date:
2017-02-28
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and
Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical
cure rates when administered 3 times a day (TID) for 3 days in participants with travelers'
diarrhea.